World News: 21:30 GMT Wednesday 11th September 2019. [Avedro, Inc via Globe Newswire via SPi World News]
WALTHAM, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: AVDR) (Avedro), today announced the inclusion of a wide array of Boost Epi-On cross-linking (CXL) presentations in the scientific and educational programs at the 10 EU Cornea Congress and the 37 Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). These presentations will unveil the early clinical experiences of several clinicians from multiple geographies who have evaluated the company’s next-generation corneal cross-linking treatment for , a debilitating eye disease that, if left untreated, can lead to loss of vision and even blindness and is one of the leading causes of corneal transplant (penetrating keratoplasty) globally.
Boost Epi-On CXL, a novel non-invasive corneal cross-linking procedure that does not require removal of the epithelium, the outermost layer of the eye, addresses the limitations of prior epi-on procedures through the addition of supplemental oxygen. Supplemental oxygen drives oxygen diffusion across the epithelium to enhance cross-linking which stabilizes and strengthens the cornea, ultimately halting or slowing disease progression. Avedro is conducting a pivotal Phase 3 clinical trial to evaluate a similar version of the Epi-On procedure in the United States for the treatment of progressive keratoconus. Enrollment was completed earlier this year.
“We believe that Boost Epi-On will increase adoption of cross-linking outside the United States because the application will appeal to patients and clinicians seeking a non-invasive procedure for keratoconus,” said Reza Zadno, PhD, Chief Executive Officer of Avedro. “What’s more, we believe the scientific presentations, coupled with Avedro’s programs at ESCRS, provide an ideal venue to educate ophthalmologists on this new technology.”
Physicians attending EU Cornea and ESCRS, held on September 14-18 in Paris, France, will have numerous opportunities to learn how Boost Epi-On CXL may benefit patients and ophthalmology practices. Clinical efficacy data and pre-clinical research will be presented during the main scientific program, and Avedro will also host a series of peer-to-peer group discussions and a . The full event schedule is below.
For more information, visit Avedro booth #B100 at ESCRS.
Globe Newswire: 21:30 GMT Wednesday 11th September 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.